Waters Parkerson & CO. LLC raised its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 8.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 918 shares of the company’s stock after acquiring an additional 68 shares during the quarter. Waters Parkerson & CO. LLC’s holdings in IDEXX Laboratories were worth $447,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Nordea Investment Management AB boosted its stake in IDEXX Laboratories by 15.5% in the 1st quarter. Nordea Investment Management AB now owns 13,719 shares of the company’s stock valued at $7,447,000 after purchasing an additional 1,839 shares during the period. Manning & Napier Advisors LLC acquired a new stake in shares of IDEXX Laboratories during the second quarter worth $20,418,000. Brevan Howard Capital Management LP bought a new stake in shares of IDEXX Laboratories in the fourth quarter valued at about $3,183,000. First Hawaiian Bank acquired a new position in shares of IDEXX Laboratories in the first quarter valued at about $982,000. Finally, Meyer Handelman Co. bought a new position in IDEXX Laboratories during the first quarter worth about $2,155,000. Institutional investors and hedge funds own 87.84% of the company’s stock.
IDEXX Laboratories Stock Up 1.1 %
NASDAQ:IDXX opened at $517.06 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.37 and a quick ratio of 1.03. IDEXX Laboratories, Inc. has a one year low of $372.50 and a one year high of $583.39. The firm’s 50 day simple moving average is $483.57 and its 200 day simple moving average is $500.01. The company has a market cap of $42.70 billion, a PE ratio of 50.05, a P/E/G ratio of 4.17 and a beta of 1.33.
Wall Street Analyst Weigh In
A number of analysts have issued reports on the stock. Piper Sandler cut their price objective on shares of IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating for the company in a report on Wednesday, August 14th. BTIG Research initiated coverage on IDEXX Laboratories in a research report on Thursday, July 25th. They set a “buy” rating and a $580.00 price target on the stock. Stifel Nicolaus dropped their price objective on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a report on Monday, June 24th. Finally, StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, July 10th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $582.25.
View Our Latest Stock Analysis on IDEXX Laboratories
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Further Reading
- Five stocks we like better than IDEXX Laboratories
- The Risks of Owning Bonds
- Roku Stock Gains New Buy Rating: Here’s Why Analysts Are Bullish
- Investing in Commodities: What Are They? How to Invest in Them
- Prepare for a Silver Surge: Best Mining Stocks to Watch Now
- Short Selling: How to Short a Stock
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.